FDA
-
-
-
-
-
-
-
Belite Bio receives orphan drug status in Switzerland for retinal therapy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Belite Bio completes enrollment in DRAGON II trial for Stargardt disease
-
-
-
-
-
-
-
Belite Bio, Inc, ADR (BLTE) PT Lowered to $98 at H.C. Wainwright
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
-
-
-
-
-
-
-
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

